collection
MENU ▼
Read by QxMD icon Read
search

Rheumatoid arthritis

shared collection
103 papers 25 to 100 followers
https://www.readbyqxmd.com/read/23104761/smoking-and-overweight-determine-the-likelihood-of-developing-rheumatoid-arthritis
#1
MULTICENTER STUDY
Maria J H de Hair, Robert B M Landewé, Marleen G H van de Sande, Dirkjan van Schaardenburg, Lisa G M van Baarsen, Danielle M Gerlag, Paul P Tak
OBJECTIVES: Rheumatoid arthritis (RA) is a prototypic chronic inflammatory disease with a debilitating course if untreated. A genetic predisposition for RA is known, and its occurrence is associated with the presence of autoantibodies in the serum and with environmental factors. It is unknown if smoking and overweight are contributory factors for developing RA in individuals with RA-specific autoantibodies in the serum. METHODS: Fifty-five individuals at risk for developing RA, based on the presence of RA-specific autoantibodies in the serum, who never had any evidence of arthritis upon physical examination, were followed over time...
October 2013: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/24934191/defining-populations-at-risk-of-rheumatoid-arthritis-the-first-steps-to-prevention
#2
REVIEW
Laura Hunt, Paul Emery
Preventing disease is a public health priority. In recent years, this focus has evolved to include noncommunicable chronic diseases such as cardiovascular disease and diabetes mellitus but is novel in rheumatic diseases such as rheumatoid arthritis (RA). In order to prevent RA, the 'at-risk' populations need to be defined. To date, a number of studies have attempted to clarify our understanding of these cohorts and how they could be identified. Suggested terminology has now been published to define individuals who might go on to develop RA...
September 2014: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/25892196/shared-epitope-antagonistic-ligands-a-new-therapeutic-strategy-in-mice-with-erosive-arthritis
#3
Song Ling, Ying Liu, Jiaqi Fu, Alessandro Colletta, Chaim Gilon, Joseph Holoshitz
OBJECTIVE: The mechanisms underlying bone damage in rheumatoid arthritis (RA) are incompletely understood. We recently identified the shared epitope (SE), an HLA-DRB1-coded 5-amino acid sequence motif carried by the majority of RA patients as a signal transduction ligand that interacts with cell surface calreticulin and accelerates osteoclast (OC)-mediated bone damage in collagen-induced arthritis (CIA). Given the role of the SE/calreticulin pathway in arthritis-associated bone damage, we sought to determine the therapeutic targetability of calreticulin...
May 2015: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28264816/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-and-biological-disease-modifying-antirheumatic-drugs-2016-update
#4
Josef S Smolen, Robert Landewé, Johannes Bijlsma, Gerd Burmester, Katerina Chatzidionysiou, Maxime Dougados, Jackie Nam, Sofia Ramiro, Marieke Voshaar, Ronald van Vollenhoven, Daniel Aletaha, Martin Aringer, Maarten Boers, Chris D Buckley, Frank Buttgereit, Vivian Bykerk, Mario Cardiel, Bernard Combe, Maurizio Cutolo, Yvonne van Eijk-Hustings, Paul Emery, Axel Finckh, Cem Gabay, Juan Gomez-Reino, Laure Gossec, Jacques-Eric Gottenberg, Johanna M W Hazes, Tom Huizinga, Meghna Jani, Dmitry Karateev, Marios Kouloumas, Tore Kvien, Zhanguo Li, Xavier Mariette, Iain McInnes, Eduardo Mysler, Peter Nash, Karel Pavelka, Gyula Poór, Christophe Richez, Piet van Riel, Andrea Rubbert-Roth, Kenneth Saag, Jose da Silva, Tanja Stamm, Tsutomu Takeuchi, René Westhovens, Maarten de Wit, Désirée van der Heijde
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib)...
March 6, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27991858/eular-definition-of-arthralgia-suspicious-for-progression-to-rheumatoid-arthritis
#5
Hanna W van Steenbergen, Daniel Aletaha, Liesbeth J J Beaart-van de Voorde, Elisabeth Brouwer, Catalin Codreanu, Bernard Combe, João E Fonseca, Merete L Hetland, Frances Humby, Tore K Kvien, Karin Niedermann, Laura Nuño, Sue Oliver, Solbritt Rantapää-Dahlqvist, Karim Raza, Dirkjan van Schaardenburg, Georg Schett, Liesbeth De Smet, Gabriella Szücs, Jirí Vencovský, Piotr Wiland, Maarten de Wit, Robert L Landewé, Annette H M van der Helm-van Mil
BACKGROUND: During the transition to rheumatoid arthritis (RA) many patients pass through a phase characterised by the presence of symptoms without clinically apparent synovitis. These symptoms are not well-characterised. This taskforce aimed to define the clinical characteristics of patients with arthralgia who are considered at risk for RA by experts based on their clinical experience. METHODS: The taskforce consisted of 18 rheumatologists, 1 methodologist, 2 patients, 3 health professionals and 1 research fellow...
March 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27697765/eular-recommendations-for-cardiovascular-disease-risk-management-in-patients-with-rheumatoid-arthritis-and-other-forms-of-inflammatory-joint-disorders-2015-2016-update
#6
R Agca, S C Heslinga, S Rollefstad, M Heslinga, I B McInnes, M J L Peters, T K Kvien, M Dougados, H Radner, F Atzeni, J Primdahl, A Södergren, S Wallberg Jonsson, J van Rompay, C Zabalan, T R Pedersen, L Jacobsson, K de Vlam, M A Gonzalez-Gay, A G Semb, G D Kitas, Y M Smulders, Z Szekanecz, N Sattar, D P M Symmons, M T Nurmohamed
Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base...
January 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27784339/bone-loss-and-aggravated-autoimmune-arthritis-in-hla-dr%C3%AE-1-bearing-humanized-mice-following-oral-challenge-with-porphyromonas-gingivalis
#7
Indra Sandal, Anastasios Karydis, Jiwen Luo, Amanda Prislovsky, Karen B Whittington, Edward F Rosloniec, Chen Dong, Deborah V Novack, Piotr Mydel, Song Guo Zheng, Marko Z Radic, David D Brand
BACKGROUND: The linkage between periodontal disease and rheumatoid arthritis is well established. Commonalities among the two are that both are chronic inflammatory diseases characterized by bone loss, an association with the shared epitope susceptibility allele, and anti-citrullinated protein antibodies. METHODS: To explore immune mechanisms that may connect the two seemingly disparate disorders, we measured host immune responses including T-cell phenotype and anti-citrullinated protein antibody production in human leukocyte antigen (HLA)-DR1 humanized C57BL/6 mice following exposure to the Gram-negative anaerobic periodontal disease pathogen Porphyromonas gingivalis...
October 26, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/27799159/patient-reported-outcomes-from-a-randomised-phase-iii-study-of-baricitinib-in-patients-with-rheumatoid-arthritis-and-an-inadequate-response-to-biological-agents-ra-beacon
#8
Josef S Smolen, Joel M Kremer, Carol L Gaich, Amy M DeLozier, Douglas E Schlichting, Li Xie, Ivaylo Stoykov, Terence Rooney, Paul Bird, Juan Miguel Sánchez Bursón, Mark C Genovese, Bernard Combe
OBJECTIVES: To assess baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthritis, who had insufficient response or intolerance to ≥1 tumour necrosis factor inhibitors (TNFis) or other biological disease-modifying antirheumatic drugs (bDMARDs). METHODS: In this double-blind phase III study, patients were randomised to once-daily placebo or baricitinib 2 or 4 mg for 24 weeks. PROs included the Short Form-36, EuroQol 5-D, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain, duration of morning joint stiffness (MJS) and Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis...
April 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27659057/rheumatoid-arthritis-patients-with-fibromyalgic-clinical-features-have-significantly-less-synovitis-as-defined-by-power-doppler-ultrasound
#9
Aneela N Mian, Khaldoun Chaabo, Julekha Wajed, Sujith Subesinghe, Nicola J Gullick, Bruce Kirkham, Toby Garrood
BACKGROUND: In patients with rheumatoid arthritis (RA) clinical measures of disease activity may not reliably discriminate between patients with active inflammatory disease and those with concomitant fibromyalgia (FM). Recent work has shown RA patients with a 28 tender joint count (TJC) minus swollen joint count (SJC) of 7 or more (joint count criteria) are more likely to meet classification criteria for FM. This study aimed to determine whether RA patients meeting clinical criteria for FM had lower levels of joint inflammation as determined by ultrasound (US)...
September 23, 2016: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/27689735/baricitinib-in-patients-with-inadequate-response-or-intolerance-to-conventional-synthetic-dmards-results-from-the-ra-build-study
#10
Maxime Dougados, Désirée van der Heijde, Ying-Chou Chen, Maria Greenwald, Edit Drescher, Jiajun Liu, Scott Beattie, Sarah Witt, Inmaculada de la Torre, Carol Gaich, Terence Rooney, Douglas Schlichting, Stephanie de Bono, Paul Emery
BACKGROUND: Baricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor. METHODS: In this phase III, double-blind 24-week study, 684 biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with rheumatoid arthritis and inadequate response or intolerance to ≥1 conventional synthetic DMARDs were randomly assigned 1:1:1 to placebo or baricitinib (2 or 4 mg) once daily, stratified by region and the presence of joint erosions. Endpoint measures included American College of Rheumatology 20% response (ACR20, primary endpoint), Disease Activity Score (DAS28) and Simplified Disease Activity Index (SDAI) score ≤3...
January 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27495156/impact-of-disease-activity-and-treatment-of-comorbidities-on-the-risk-of-myocardial-infarction-in-rheumatoid-arthritis
#11
Yvette Meissner, Angela Zink, Jörn Kekow, Karin Rockwitz, Anke Liebhaber, Silke Zinke, Kerstin Gerhold, Adrian Richter, Joachim Listing, Anja Strangfeld
BACKGROUND: The aim was to estimate the impact of individual risk factors and treatment with various disease-modifying antirheumatic drugs (DMARDs) on the incidence of myocardial infarction (MI) in patients with rheumatoid arthritis (RA). METHODS: We analysed data from 11,285 patients with RA, enrolled in the prospective cohort study RABBIT, at the start of biologic (b) or conventional synthetic (cs) DMARDs. A nested case-control study was conducted, defining patients with MI during follow-up as cases...
August 5, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/27546493/self-limiting-arthritis-among-patients-fulfilling-the-2010-acr-eular-classification-criteria-for-rheumatoid-arthritis-in-a-very-early-arthritis-cohort
#12
Ellen Sauar Norli, Gina H Brinkmann, Tore K Kvien, Olav Bjørneboe, Anne J Haugen, Halvor Nygaard, Cathrine Thunem, Elisabeth Lie, Maria D Mjaavatten
OBJECTIVES: To study occurrence of and factors associated with self-limiting arthritis among patients fulfilling the 2010 ACR/EULAR classification criteria for rheumatoid arthritis (RA) (2010 RA criteria) in patients with ≤16 weeks׳ duration of joint swelling. METHODS: We applied the 2010 RA criteria in 1118 patients included in a 2-year longitudinal cohort. In all, 256 patients fulfilled the 2010 RA criteria at baseline; outcome was defined as either "self-limiting arthritis" (no DMARD use during follow-up, no swollen joints at last assessment, and no final clinical diagnosis of RA) or "persistent disease...
December 2016: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/27502891/risk-of-lymphoma-in-patients-exposed-to-antitumour-necrosis-factor-therapy-results-from-the-british-society-for-rheumatology-biologics-register-for-rheumatoid-arthritis
#13
Louise K Mercer, James B Galloway, Mark Lunt, Rebecca Davies, Audrey L S Low, William G Dixon, Kath D Watson, Deborah P M Symmons, Kimme L Hyrich
OBJECTIVES: Patients with rheumatoid arthritis (RA) are at increased risk of lymphoma compared with the general population. There are concerns that tumour necrosis factor inhibitors (TNFi) may exacerbate this risk. However, since the excess risk of lymphoma in RA is related to the cumulative burden of inflammation, TNFi may conversely reduce the risk of lymphoma by decreasing the burden of inflammation. The aim of this study was to compare the risk of lymphoma in subjects with RA treated with TNFi with those treated with non-biological therapy...
March 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27373893/components-of-treatment-delay-in-rheumatoid-arthritis-differ-according-to-autoantibody-status-validation-of-a-single-centre-observation-using-national-audit-data
#14
Arthur G Pratt, Dennis Lendrem, Ben Hargreaves, Osman Aslam, James B Galloway, John D Isaacs
OBJECTIVE: To determine whether time to treatment following symptom onset differs between RA patients according to autoantibody status. METHODS: A single-centre retrospective analysis of a UK early RA inception cohort was first undertaken to identify those components of the patient journey that differed by serological subtype. Data from a UK national audit of early inflammatory arthritis patients was accessed to replicate the key finding. RESULTS: A total of 173 RA patients were diagnosed over a 31-month period, of whom 80 (46%) were ACPA/RF double-seropositive (ACPA(+)/RF(+)), 53 (31%) ACPA(-)/RF(-), 17 (10%) ACPA(+)/RF(-) and 23 (13%) RF(+)/ACPA(-) Overall, ACPA(+)/RF(+) patients experienced significantly longer symptom duration before DMARD initiation...
October 2016: Rheumatology
https://www.readbyqxmd.com/read/27382171/vagus-nerve-stimulation-inhibits-cytokine-production-and-attenuates-disease-severity-in-rheumatoid-arthritis
#15
Frieda A Koopman, Sangeeta S Chavan, Sanda Miljko, Simeon Grazio, Sekib Sokolovic, P Richard Schuurman, Ashesh D Mehta, Yaakov A Levine, Michael Faltys, Ralph Zitnik, Kevin J Tracey, Paul P Tak
Rheumatoid arthritis (RA) is a heterogeneous, prevalent, chronic autoimmune disease characterized by painful swollen joints and significant disabilities. Symptomatic relief can be achieved in up to 50% of patients using biological agents that inhibit tumor necrosis factor (TNF) or other mechanisms of action, but there are no universally effective therapies. Recent advances in basic and preclinical science reveal that reflex neural circuits inhibit the production of cytokines and inflammation in animal models...
July 19, 2016: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/27338778/adalimumab-long-term-safety-infections-vaccination-response-and-pregnancy-outcomes-in-patients-with-rheumatoid-arthritis
#16
Gerd R Burmester, Robert Landewé, Mark C Genovese, Alan W Friedman, Nathan D Pfeifer, Nupun A Varothai, Ana P Lacerda
BACKGROUND: Adalimumab has been used in patients with moderately to severely active rheumatoid arthritis (RA) for over 10 years and has a well-established safety profile across multiple indications. OBJECTIVE: To update adverse events (AEs) of special interest from global adalimumab clinical trials in patients with RA. METHODS: This analysis includes 15 132 patients exposed to adalimumab in global RA clinical trials. AEs of interest included overall infections, laboratory abnormalities and AEs associated with influenza vaccination...
February 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/26097231/cause-specific-mortality-in-male-us-veterans-with-rheumatoid-arthritis
#17
Bryant R England, Harlan Sayles, Kaleb Michaud, Liron Caplan, Lisa A Davis, Grant W Cannon, Brian C Sauer, Elizabeth B Solow, Andreas M Reimold, Gail S Kerr, Pascale Schwab, Josh F Baker, Ted R Mikuls
OBJECTIVE: There has been limited investigation into cause-specific mortality and the associated risk factors in men with rheumatoid arthritis (RA). We investigated all-cause and cause-specific mortality in men with RA, examining determinants of survival. METHODS: Men from a longitudinal RA registry were followed from enrollment until death or through 2013. Vital status and cause of death were determined using the National Death Index. Crude mortality rates and standardized mortality ratios (SMRs) were calculated for all-cause, cardiovascular disease (CVD), cancer, and respiratory mortality...
January 2016: Arthritis Care & Research
https://www.readbyqxmd.com/read/27185957/disease-modifying-anti-rheumatic-drugs-and-non-melanoma-skin-cancer-in-inflammatory-arthritis-patients-a-retrospective-cohort-study
#18
Eva Lange, Leigh Blizzard, Alison Venn, Hilton Francis, Graeme Jones
OBJECTIVES: The aim was to determine the non-melanoma skin cancer (NMSC) risk in patients with RA or PsA exposed to MTX and other DMARDs. METHODS: Information on medication was collected on 405 patients with RA or PsA in two private rheumatology practices and was matched to comprehensive histologically confirmed cancer registry data for the years 1978-2005. Relative risks (RRs) were estimated by logarithmic binomial modelling, and standardized incidence ratios (SIRs) were calculated from year-, sex- and age-specific rates of NMSC for the local population...
September 2016: Rheumatology
https://www.readbyqxmd.com/read/27159882/interleukin-9-and-t-helper-type-9-cells-in-rheumatic-diseases
#19
REVIEW
F Ciccia, G Guggino, A Ferrante, P Cipriani, R Giacomelli, G Triolo
Interleukin (IL)-9 is a 28-30 kDa monomeric glycosylated polypeptide belonging to the IL-7/IL-9 family of proteins that bind to a composite receptor consisting of the private receptor IL-9R and the IL-2 receptor, gamma (IL-2RG), a common gamma subunit shared by the receptors of many different cytokines. The IL-9R is expressed widely and IL-9 impacts a number of effector cells, such as effector T cells, B cells, innate lymphoid cells, mast cells, polymorphonuclear cells, epithelial cells and smooth muscle cells, playing an important role in regulating inflammatory immunity...
August 2016: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/27215344/circulating-secretory-iga-antibodies-against-cyclic-citrullinated-peptides-in-early-rheumatoid-arthritis-associate-with-inflammatory-activity-and-smoking
#20
Karin Roos, Klara Martinsson, Michael Ziegelasch, Yngve Sommarin, Anna Svärd, Thomas Skogh, Alf Kastbom
BACKGROUND: A possible association between mucosal immunization and inflammation, as well as the initiation and propagation of rheumatoid arthritis (RA), is attracting renewed interest. The aim of this study was to evaluate the possible occurrence and clinical correlations of circulating secretory immunoglobulin A (SIgA) antibodies against the second-generation cyclic citrullinated peptides (CCP) among patients with recent-onset RA followed prospectively over 3 years. METHODS: Baseline serum samples from 636 patients with recent-onset RA were analyzed for SIgA anti-CCP antibodies by using an enzyme-linked immunosorbent assay with a secondary antibody directed against secretory component...
May 23, 2016: Arthritis Research & Therapy
label_collection
label_collection
5160
1
2
2016-05-27 11:21:00
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"